High Risk Infants who are Low Dose Tolerant after Peanut Oral Food Challenges

Adora Lin; Burcin Uygungil; Karen Robbins; Olivia Ackerman; Hemant Sharma

doi:10.1101/2020.01.31.20019570

Abstract

Background Early peanut (PN) introduction may prevent peanut allergy in at-risk children. Little data exists regarding early introduction for infants with large skin prick tests (SPT) or high peanut IgE levels, who are not often offered oral food challenges (OFC).

Objective To retrospectively assess tolerance of a low dose (1 gram) of peanut in infants at risk for peanut allergy, including highest-risk infants (HRI) with SPT wheal >7mm.

Methods We reviewed PN OFCs performed over a two-year period at our pediatric allergy center. Low-dose PN OFC was offered to all infants considered at risk for PN allergy, regardless of peanut SPT or IgE results. Dosing was escalated after OFC at home.

Results Of infants with SPT wheal <=4 mm (n=30), 29 (97%) were low-dose-tolerant. Of those with SPT >4 mm (n=40), 25 (63%) were low-dose-tolerant, and Ara h2 IgE was significantly lower compared to non-tolerant individuals (median 0.62 versus 6.49 kU/L, p<0.05). Among HRI with SPT >7mm (n=22), 12 (55%) were tolerant, with median SPT 9mm (range 8-11mm), PN-IgE 1.1 kU/L (0.3-10.7 kU/L) and Ara h2 1.6 kU/L (0-9.57 kU/L). Age, sex, race, eczema, and egg sensitization did not affect tolerance regardless of SPT size. After 3-6 months, most infants tolerant at OFC were gradually able to consume larger doses of PN.

Conclusion Many infants with PN-SPT >4mm are tolerant of low-dose peanut, and Ara h 2 IgE may be predictive for clinical tolerance among these infants. Low-dose PN-OFC with gradual updosing may help prevent PN allergy in a greater number of at-risk infants.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

There was no funding source for this project.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

B.U., A.L., K.R., O.A., and H.S. substantially contributed to conception and design, data analysis and interpretation, article drafting, and critical review of the manuscript.
All authors have given final approval of this manuscript and agree to be accountable for all aspects of the work related to its accuracy and integrity.
Conflicts of interest: None
Funding source: None